•Anixa Biosciences announced the treatment of the first patient in the fifth cohort of its Phase 1 clinical trial for FSHR-targeted CAR-T therapy in recurrent ovarian cancer.
•No dose-limiting toxicities have been observed to date, with some patients surviving more than one year and one beyond two years.
•Meta stock rose 3.01% as aggressive AI infrastructure spending is increasingly viewed as a potential revenue stream through an internal AI cloud business.
•Boeing stock climbed 3.29% following Q2 deliveries that exceeded estimates and the launch of a fourth 737 MAX assembly line.
•Fitch Ratings upgraded Boeing's credit outlook from stable to positive, boosting investor optimism.
